IP Verse

Teva Pharmaceuticals competitive analysis

Latest oppositions filed by Teva Pharmaceuticals

Explore patent oppositions filed by Teva Pharmaceuticals against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Aug 27, 2026
Patent NumberTitleApplicantOpposition Date
EP2952177
Compositions Comprising Sphingosine I Phosphate (Sip) Receptor ModulatorsNOVARTISMay 4, 2023
EP2952177
Compositions Comprising Sphingosine I Phosphate (Sip) Receptor ModulatorsNOVARTISSep 22, 2022
EP2914255
Treatment Or Prevention Of Cardiovascular Events Via The Administration Of A Colchicine DerivativeMURRAY & POOLE ENTERPRISESApr 21, 2022
EP1746976
Liposomes Useful For Drug DeliveryHERMES BIOSCIENCESOct 11, 2017
EP2680841
Use Of Glycopyrrolate For Treating TachycardiaHEPTARES THERAPEUTICSSep 27, 2017
EP2906218
Beta-2-Adrenoceptor Agonist For The Treatment Of CoughBOEHRINGER INGELHEIMSep 13, 2017
EP2269603
Treatment Of Solid Tumours With Rapamycin DerivativesNOVARTISFeb 18, 2016

Latest patents of Teva Pharmaceuticals opposed by its competitors

Explore Teva Pharmaceuticals's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Aug 27, 2026
Patent NumberPublication DateTitleTotal Oppositions
EP3798224
Mar 19, 2025Solid State Forms Of Ixazomib Citrate1
EP4097091
Sep 18, 2024Solid State Forms Of Mavacamten And Process For Preparation Thereof3
EP3497104
Oct 6, 2021Solid State Forms Of Lumateperone Ditosylate Salt1
EP3344607
Nov 6, 2019Solid State Forms Of Selexipag2
EP2897588
Jul 17, 2019An Inhalable Medicament1
EP3143998
May 22, 2019An Inhalable Medicament Comprising Tiotropium1
EP3045182
Mar 7, 2018Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide And Methods Using Same2
EP2800567
Sep 27, 2017An Inhaler Comprising A Tiotropium-Containing-Composition2
EP2688877
Mar 8, 2017Solid State Forms Of Cabazitaxel And Processes For Preparation Thereof1
EP2793886
Aug 24, 2016An Inhalable Medicament Comprising Tiotropium1

Latest PTAB cases involving Teva Pharmaceuticals

Discover the latest PTAB cases involving Teva Pharmaceuticals, highlighting their recent legal challenges and patent disputes.

Last updated on: Aug 28, 2026
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Teva Pharmaceuticals

IPR2022-01513Sep 9, 2022TEVA PHARMACEUTICALSBAYER PHARMATerminated-Adverse Judgment
IPR2022-00796Apr 11, 2022ELI LILLYTEVA PHARMACEUTICALSFinal Written Decision
IPR2022-00738Mar 23, 2022ELI LILLYTEVA PHARMACEUTICALSFinal Written Decision
IPR2022-00739Mar 23, 2022ELI LILLYTEVA PHARMACEUTICALSFinal Written Decision
IPR2020-01045Jun 10, 2020TEVA PHARMACEUTICALSCYPESTerminated-Settled
IPR2020-01045Jun 10, 2020TEVA PHARMACEUTICALSMERCK SHARP & DOHMETerminated-Settled
PGR2019-00048May 7, 2019TEVA PHARMACEUTICALSCORCEPT THERAPEUTICSFinal Written Decision
IPR2018-01711Oct 1, 2018ELI LILLYTEVA PHARMACEUTICALSFinal Written Decision
IPR2018-01712Oct 1, 2018ELI LILLYTEVA PHARMACEUTICALSFinal Written Decision
IPR2018-01710Sep 28, 2018ELI LILLYTEVA PHARMACEUTICALSFinal Written Decision

Peer Comparison New

IP litigation analysis comparing Teva Pharmaceuticals with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Aug 27, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
TEVA PHARMACEUTICALS5201712
CHIESI FARMACEUTICI1123 - -
ELI LILLY18341715
HAMM&WITTKOPP PATENTANWÄLTE PARTMBB81 - - -